Compare BNGO & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNGO | BFRI |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | 94 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 13.2M |
| IPO Year | 2018 | N/A |
| Metric | BNGO | BFRI |
|---|---|---|
| Price | $1.09 | $1.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | $2.75 |
| AVG Volume (30 Days) | 97.1K | ★ 367.7K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,000,735.00 | N/A |
| Revenue This Year | $14.99 | $14.36 |
| Revenue Next Year | $34.73 | $16.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $1.06 | $0.57 |
| 52 Week High | $5.50 | $1.21 |
| Indicator | BNGO | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 61.66 |
| Support Level | $1.08 | $0.71 |
| Resistance Level | $1.19 | N/A |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 14.29 | 89.74 |
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.